Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy for bacterial vaginosis shows promise in clinical trial

NCT ID NCT07247851

Disease control Sponsor: Ain Shams Maternity Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding a vaginal clindamycin cream to standard oral metronidazole works better than oral metronidazole alone for treating bacterial vaginosis. One hundred women with confirmed BV took part. The goal was to see if the combination relieved symptoms like discharge and odor more effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Jan 2024

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged ≥ 18 years with a clinical diagnosis and laboratory diagnosis as (cervical smear \& high vaginal swab) of bacterial vaginosis. * Diagnosed with Bacterial vaginosis the Amsel scoring system which requires 3 criteria of 4 criteria for diagnosis.: * The presence of homogeneous, thin, greyish white vaginal discharge. * Vaginal pH over 4.5. * Positive whiff-amine test (the presence of a fishy odor following addition of KOH to the vaginal sample). * More than 20% clue cells/high power field on a wet mount of vaginal secretions. Exclusion Criteria: * Other types of infections based on history and clinical examination as candida vaginitis (itching with cottage cheese whitish discharge, Trichomonas vaginalis (with yellowish green offensive discharge) and any sexually transmitted disease (STDs) as gonorrhea(watery creamy greenish discharge, pain on micturation)syphilis(appearance of shung-kur ulcer, painless sore), chlamydia(abnormal discharge from vagina, burning sensation on peeing, abnormal discharge from penis) or genital herpes (tingling, burning, itching around genitals on both parteners). * Pregnant and lactating females * Any contraindication or hypersensitivity to metronidazole use * Use of other antibiotics or systemic antifungal agents within the previous 2 weeks or planned use within 2 weeks * Use of topical vaginal antibiotics, antifungals or acidifying products recently or planned within 2 weeks * Atrophic vaginitis * Using IUD as contraceptive method because IUD is a risk factor for infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacterial vaginosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial vaginosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bacterial vaginosis

Contacts and locations

Locations

  • Ain Shams Maternity Hospital

    Cairo, Abbasia, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.